SCHEMBL24257835

SCHEMBL24257835

CCOC(=O)CNC(=O)c1ncc(-c2cccc(Cl)c2)c(C)c1OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
VEGFA P15692 4/20 0.49
FLT1 P17948 4/20 0.49
EGLN1 Q9GZT9 4/20 0.49
EGLN3 Q9H6Z9 4/20 0.49
TET3 O43151 1/20 0.45
BBOX1 O75936 1/20 0.45
ASPH Q12797 1/20 0.45
TET2 Q6N021 1/20 0.45
KDM8 Q8N371 1/20 0.45
OGFOD1 Q8N543 1/20 0.45
TET1 Q8NFU7 1/20 0.45
HIF1AN Q9NWT6 1/20 0.45
MAPT P10636 4/20 0.43
GPR119 Q8TDV5 1/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
PPID Q08752 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452770 1.00 VEGFA (0.49) VEGFAFLT1EGLN1EGLN3TET3
SCHEMBL24257548 0.89 EGLN1 (0.46) VEGFAFLT1EGLN1EGLN3MAPT
SCHEMBL30452640 0.89 EGLN1 (0.46) VEGFAFLT1EGLN1EGLN3MAPT
SCHEMBL30452826 0.89 GAA (0.48) EGLN1MAPTKMT2AMEN1TDP1
SCHEMBL24257686 0.89 GAA (0.48) EGLN1MAPTKMT2AMEN1TDP1
SCHEMBL24257806 0.89 EGLN1 (0.44) EGLN1BBOX1ASPHKDM8MAPT
SCHEMBL30452435 0.88 VEGFA (0.45) VEGFAFLT1EGLN1EGLN3TET3
SCHEMBL24257853 0.88 VEGFA (0.45) VEGFAFLT1EGLN1EGLN3TET3
SCHEMBL24257792 0.86 EGLN1 (0.46) EGLN1EGLN3MAPTKMT2AMEN1
SCHEMBL30452692 0.86 EGLN1 (0.46) EGLN1EGLN3MAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2023-09-21 US disclosed
WO-2022036188-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE AKEBIA THERAPEUTICS, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295110-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE HIF1AN, EGLN3, PHF20 VEGFA 1862/4885FLT1 414/4885EGLN1 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.